GET DAILY SIGNALSWhy Is DexCom (DXCM) Stock Down -5.80% Today?
Key Takeaways
- DXCM shares fell roughly 5.8% in Wednesday's session, trading near $80.77 versus a prior close of $85.74.
- The primary catalyst was a read-through from rival ABT's third-quarter report, which showed sequential deceleration in continuous glucose monitor (CGM) sales.
- Abbott also trimmed its full-year organic sales growth outlook, raising doubts about the near-term growth trajectory of the broader CGM market.
- The selling arrived just over a week before DexCom's own third-quarter earnings report, amplifying investor caution.
- Traders are now focused on DexCom's October 29 results and any signals on CGM demand and Medicare coverage.
Opening Summary
DexCom, Inc. (DXCM), the San Diego-based maker of continuous glucose monitoring systems, saw its stock slide sharply on Wednesday. Shares fell about 5.8%, declining to roughly $80.77 from a previous-session close of $85.74, confirming a clear move lower. The decline was driven less by DexCom-specific news and more by a sector-wide reassessment after Abbott Laboratories reported third-quarter results that pointed to slowing momentum in the continuous glucose monitoring category — a dynamic that carries direct implications for DexCom, a pure-play CGM leader.
Abbott's Results Cast a Shadow Over the CGM Category
The most immediate catalyst behind the DXCM decline was the market's reaction to Abbott Laboratories' third-quarter earnings. Abbott reported that sales of its FreeStyle Libre continuous glucose monitors grew 7.3% on a reported basis and 7.7% on a comparable basis. While still positive, that represented a sequential deceleration from earlier periods and fell short of the stronger trajectory some investors had anticipated.
Because DexCom and Abbott are the two dominant players in the CGM market, Abbott's results are closely watched as a barometer for the entire category. Analysts noted that the slower CGM growth "calls into question the durability of growth" for the segment, especially ahead of a potential Medicare coverage decision for type 2 diabetes patients. That read-through weighed directly on DexCom, which has no diversified business lines to offset any softening in glucose monitoring demand.
Guidance Cut Reinforces Growth Concerns
Adding to the pressure, Abbott lowered its full-year organic sales growth outlook to approximately 6%, down from a prior range of 6.5% to 7.5%. The reduction signaled that management sees moderating momentum across its portfolio, with medical device segments including diabetes care contributing to the softer view. For DexCom investors, the guidance revision underscored the risk that the broader diabetes-technology market may be entering a period of slower growth, even as DexCom has been expanding into new patient populations and international markets.
Market Context and Trading Activity
The DXCM decline came against a backdrop of uneven sentiment across the healthcare and medical-device complex. The stock's move lower was broadly consistent with the CGM peer group, as Abbott shares also wavered during the session despite the diversified company's in-line overall results. The action reflected sector positioning and a re-rating of near-term growth expectations rather than a change in DexCom's competitive standing, which remains strong following recent positive study data and analyst price-target increases.
From a technical standpoint, the decline pushed DXCM back below its 50-day moving average, a level that had provided support in recent weeks. The pullback also marked a retreat from the stock's 52-week high near $92.59, leaving traders to watch whether the $79–$80 zone can hold as a floor into the company's upcoming earnings report.
What Comes Next for DXCM
The next major test for DXCM arrives on October 29, 2026, when the company reports third-quarter results. Investors will be looking for evidence that DexCom's own growth remains resilient despite the category-wide slowdown suggested by Abbott's numbers. Key areas of focus will include U.S. and international revenue growth, the ongoing ramp of the G7 15-day sensor, gross margin trends, and any update on the company's full-year outlook.
Beyond earnings, the market remains attuned to regulatory developments. A potential Medicare coverage determination for continuous glucose monitoring in non-insulin type 2 diabetes patients is expected before year-end, with implementation anticipated in 2027. That decision could meaningfully expand the addressable market and is viewed as one of the most significant longer-term catalysts for the entire CGM industry. Competitive dynamics with Abbott's Lingo and other offerings, as well as broader healthcare-sector fund flows, will continue to influence sentiment in the near term.
Trending AI Robots
For traders seeking a data-driven edge in volatile markets, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing automated strategies. Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, helping investors identify approaches aligned with their own goals. Explore the Trending AI Robots page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
DXCM in downward trend: 10-day moving average crossed below 50-day moving average on October 06, 2026
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DXCM moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 58 cases where DXCM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DXCM as a result. In 58 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on October 16, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
Following a +1.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 204 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.343) is normal, around the industry mean (2.979). P/E Ratio (33.233) is within average values for comparable stocks, (2.590). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices and glucose monitoring systems
Industry MedicalNursingServices
Advertisement